Target Information

Target General Infomation
Target ID
T95399
Target Name
Myophosphorylase
Target Type
Discontinued
Disease Chronic lymphocytic leukaemia [ICD10: C91]
Type 2 diabetes [ICD9: 250; ICD10: E11]
BioChemical Class
Transferases (EC:2)
EC Number
EC 2.4.1.1
Drugs and Mode of Action
Drug(s) Flavopiridol Drug Info Discontinued in Phase 3 Chronic lymphocytic leukaemia [537114], [541024]
PSN357 Drug Info Discontinued in Phase 2 Type 2 diabetes [547993]
GSK-1362885 Drug Info Discontinued in Phase 1 Type 2 diabetes [522855]
Inhibitor Flavopiridol Drug Info [549823]
Modulator GSK-1362885 Drug Info [1572591]
PSN357 Drug Info
References
Ref 522855ClinicalTrials.gov (NCT01013766) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics. U.S. National Institutes of Health.
Ref 537114Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
Ref 541024(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5680).
Ref 547993Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021020)
Ref
Ref 549823Pharma & Vaccines. Product Development Pipeline. April 29 2009.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.